Deeks 2003.

Methods	N= 24 Non randomized, Fup=109 weeks, w/o d/o reported
Participants	Eligibility:‐ VL >2500 copies for 6months; ART: PI* 12 months, Stable ART for 4 months; ART duration 27 weeks (25‐33) Baseline CD4 218 (80‐298); Baseline VL 4.6 (3.9‐5.1);
Interventions	20 wks TI
Outcomes	STI arm: CD4 decline: 108 cells/mm3 VL rebound: + 0.76 log cop/ml Adverse events: Pneumocystis carinii pneumonia, thrombocytopenia; peripheral neuropathy
Notes	Durable viral suppression achieved with use of one fully active drug
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used